logo
Scientists Have Figured Out Exactly How Much Time Drinking Takes Off Your Life

Scientists Have Figured Out Exactly How Much Time Drinking Takes Off Your Life

Yahoo6 days ago

Recently, there's been a lot of talk about the negative effects of drinking alcohol. In December of last year, the U.S. Surgeon General released an advisory warning about the direct relationship between alcohol consumption and cancer. Around the same time, new research challenged long-held beliefs about the safety of moderate drinking.
In a study published in the Journal of Studies on Alcohol and Drugs, Dr. Tim Stockwell and colleagues found that even low levels of alcohol consumption are linked to increased mortality. Dr. Stockwell later estimated, in media interviews, how this risk might translate into days or years of life lost depending on drinking level. He told the Daily Mail that consuming just two drinks per week may shorten your life by three to six days.
And unfortunately, for frequent imbibers, the numbers get even bleaker. According to Dr. Stockwell's comments to the media, if a person were to drink seven alcoholic beverages a week (beer, wine, or spirits), they risk cutting their life expectancy by two and a half months. A person who drinks 35 alcoholic beverages a week could shorten their life by two years, based on his interpretation of the research.
Dr. Stockwell told the Daily Mail that these numbers are averages, and some people could end up luckier than others. He discouraged people from considering alcohol as something that is okay or even healthy to consume in moderation.
The CDC defines moderate drinking as one drink or less per day for women and two or less for men. For years, moderate drinking was considered okay, if not beneficial. However, Dr. Stockwell's research—and a 2023 meta-analysis he co-authored, which analyzed 107 studies from over 40 years—disputed that belief.
"Dr. Stockwell's review of years of research really challenges the old idea that a little alcohol is good for you. What he and his team found is that even small amounts of alcohol can shorten your lifespan," Dr. Raj Dasgupta, Chief Medical Advisor for Sleepopolis tells Delish.
Dr. Dasgupta explains that both how much you drink and how often you drink impacts life expectancy. And as drinking increases, he says there's a greater risk to long-term health, such as liver problems, cancer, heart disease, and accidents.
"Alcohol's effect on each person is different. My advice: if you do drink, try to keep it in moderation," he says.
You Might Also Like
Insanely Easy Weeknight Dinners To Try This Week
29 Insanely Delicious Vodka Cocktails

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

5 Must-Read Analyst Questions From Astrana Health's Q1 Earnings Call
5 Must-Read Analyst Questions From Astrana Health's Q1 Earnings Call

Yahoo

timean hour ago

  • Yahoo

5 Must-Read Analyst Questions From Astrana Health's Q1 Earnings Call

Astrana Health's first quarter results for 2025 were met with a negative market reaction, with revenue growth driven by its Care Partners segment and progress in full-risk contracts. However, management acknowledged that the quarter's performance was tempered by lower-than-expected revenue and compressed operating margins. CEO Brandon Sim pointed to the flu season and higher emergency room and lab utilization in Medicaid as factors impacting costs, while also highlighting ongoing investments in technology and integration. Sim stated, 'Margins were moderated by planned ongoing investments in growth integration technology, as well as by revenue growth in areas with lower near-term margin profiles.' Is now the time to buy ASTH? Find out in our full research report (it's free). Revenue: $620.4 million vs analyst estimates of $636.2 million (53.4% year-on-year growth, 2.5% miss) Adjusted EPS: $0.34 vs analyst estimates of $0.33 (in line) Adjusted EBITDA: $36.39 million vs analyst estimates of $35.7 million (5.9% margin, 1.9% beat) The company reconfirmed its revenue guidance for the full year of $2.6 billion at the midpoint EBITDA guidance for the full year is $180 million at the midpoint, below analyst estimates of $181.2 million Operating Margin: 3.3%, down from 7.5% in the same quarter last year Market Capitalization: $1.23 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Ryan Daniels (William Blair) asked about remaining milestones for CHS integration. CEO Brandon Sim explained integration is complete, but further implementation of the care model should drive margin improvements over time. Michael Ha (Baird) pressed on the seasonality and drivers behind the lighter revenue outlook for next quarter. Sim attributed this to Medicaid volatility and full-risk conversions being weighted toward the second half of the year. Jack Slevin (Jefferies) questioned Astrana's confidence in leveraging favorable Medicare Advantage rates. Sim responded that while the rate update was anticipated, its exact financial impact will become clearer as more details emerge. Jailendra Singh (Truist Securities) asked about profitability in the ACO REACH program and the impact of recent risk adjustment changes. Sim shared that the company absorbed a modest drag from retroactive adjustments, offset by other risk-management strategies. Brooks O'Neil (Lake Street Capital Markets) probed on organizational stress from rapid growth and integration. Sim acknowledged the challenges of scaling rapidly, emphasizing ongoing focus on integration and cultural cohesion. In the upcoming quarters, the StockStory team will be monitoring (1) the pace and effectiveness of integrating Prospect Health and realizing promised synergies, (2) the continued conversion of members to full-risk contracts and resulting margin trends, and (3) the outcome of Medicaid contract renewals and regulatory developments in key states. Progress in leadership-driven data and technology initiatives will also be a key signpost for sustainable growth. Astrana Health currently trades at $24.73, down from $33.40 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

EPA employees put names to 'declaration of dissent' over agency moves under Trump
EPA employees put names to 'declaration of dissent' over agency moves under Trump

Washington Post

timean hour ago

  • Washington Post

EPA employees put names to 'declaration of dissent' over agency moves under Trump

A group of Environmental Protection Agency employees on Monday published a declaration of dissent from the agency's policies under the Trump administration, saying they 'undermine the EPA mission of protecting human health and the environment.' More than 170 EPA employees put their names to the document, with about 100 more signing anonymously out of fear of retaliation, according to Jeremy Berg, a former editor-in-chief of Science magazine who is not an EPA employee but was among non-EPA scientists or academics to also sign. The latter figure includes over 70 Nobel laureates.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store